You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 278 No. 23, December 17, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorials
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Primary Angioplasty Compared With Thrombolytic Therapy for Acute Myocardial Infarction

Salim Yusuf, FRCP, DPhil; Janice Pogue, MSc

JAMA. 1997;278(23):2110-2111.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of THE JOURNAL, Weaver and colleagues1 provide a careful quantitative review of the available data from randomized trials comparing primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy in patients with acute myocardial infarction. This analysis of 10 trials includes 2606 patients and reports a reduction in mortality (odds ratio, 0.66; 95% confidence interval [CI], 0.46-0.94), in the composite of mortality and reinfarction (odds ratio, 0.58; 95% CI, 0.44-0.76), and in stroke (odds ratio, 0.35; 95% CI, 0.14-0.77) with the use of PTCA. However, before the data from these analyses are considered persuasive enough to conclusively establish the superiority of primary PTCA over thrombolytic therapy, 3 key questions must be addressed.

See also p 2093.

First, are there potential biases that could have inflated the results of the individual trials or this meta-analysis? Several potential biases both within each trial and in the authors' metaanalysis should . . . [Full Text PDF of this Article]


Author Affiliations

From the Division of Cardiology, McMaster University (Dr Yusuf), and Preventive Cardiology and Therapeutic Research Program, Hamilton Health Sciences Corporation Research Centre (Dr Yusuf and Ms Pogue), Hamilton, Ontario.


Footnotes

Corresponding author: Salim Yusuf, FRCP, DPhil, Hamilton General Hospital, 237 Barton St E,Hamilton, Ontario, Canada L8L 2x2(e-mail:yusufs@fhs.csu.mcmaster.ca).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.